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A monosialoganglioside, W-NeuNAcLcOse,Cer, has recently been detected in colorectal carcinoma cells, small cell lung 
carcinoma cells, embryonal carcinoma cells and in human brain extracts. We report here the presence of a CMP-sialic: 
LcOse,Cer sialyl transferase activity in subcellular membrane fractions of the human colorectal carcinoma, SW1 116, 
which recognizes the non-reducing terminal galactosyl moiety of lactotetraosylceramide. A convenient method for struc- 
tural analysis of picomolar quantities of the radioactive nzymatic product(s) using bacterial endoglycoceramidase, iali- 
dase and a viral sialidase is presented. 
Glycolipid; Ganglioside; Transferase; Sialidase; (Carcinoma cell) 
1. INTRODUCTION 
Following the report of a monoclonal antibody 
(C-50) which reacts with monosialogangliosides of
the lacto-series, a glycolipid antigen was 
discovered in lung carcinoma cells defined by the 
structure IV3-NeuNAcLcOseKer [ 11. Subsequent- 
ly it has also been reported to be present in em- 
bryonal carcinoma cells [2] and in minor quantities 
in the human brain [3]. We have previously 
reported the biosynthesis of Lewisa, Lewisb and 
H-l fucolipids, via fucosylation of lacto- 
tetraosylceramide, by enzymatic activities in colo- 
rectal carcinoma Golgi and post-Golgi subcellular 
fractions [4]. The purpose of the present study was 
to demonstrate sialylation of lactotetra- 
osylceramide via transferase activity in human col- 
orectal carcinoma cell (SW 1116) membranes which 
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Abbreviations: HPTLC, high performance thin-layer 
chromatography; Mab, monoclonal antibody; IV’- 
NeuNAcLcOse&er, NeuNAc(cu2-3)Gal~1-+3)GlcNAc- 
031-3)Gal691*4)GlcCer (Nomenclature of glycolipids 
according to the IUPAC-IUB commission on biochemical 
nomenclature [(1977) Eur. J. Biochem. 79, 11-211) 
directs N-acetylneuraminic acid to the non- 
reducing terminal galactosyl moiety. 
Our results are the first to describe an ~2-3 
sialyl transferase for lactotetraosylceramide of 
documented purity and structure, which is respon- 
sible for the biosynthesis of IV3-NeuNAcLc- 
Ose&er, the putative precursor of the 19-9 
glycolipid antigen [5]. We also demonstrate that 
under controlled incubation conditions bacterial 
and viral sialidases are useful for structure analyses 
of gangliosides in picomolar quantities, where 
chemical modification is impractical. 
2. MATERIALS AND METHODS 
2.1. Materials 
SW1 116 cells were cultured in serum-free media, harvested 
and washed as described [6]. Lactotetraosylceramide was kindly 
provided by Dr G&an Larson (Dept of Clinical Chemistry, 
Sahlgren’s Hospital, University of Giiteborg, Sweden). Authen- 
tic IV’-NeuNAcLcOse&er and C-50 MAb were kindly provid- 
ed by Drs Lars Svennerholm and Pam Fredman (Dept of 
Neurochemistry, Sahlgren’s Hospital, University of Giiteborg, 
Sweden). Authentic IV6-NeuNAcnLcOse&er was kindly pro- 
vided by Dr Olle Nilsson (University of Giiteborg). En- 
doglycoceramidase from Rhodococcus was a generous gift of 
Dr T. Yamagata (Mitsubishi Company, Glycoconjugate 
Research Division, Japan). Influenza sialidase was obtained 
through the good offices of Dr J.J. Skehel (National Research 
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Institute, Mill Hill, London, England). Bacterial sialidases were CHCls/CH3OH (3% HzO) and allowed to sit overnight at 4°C 
obtained from Boehringer-Mannheim (FRG). CMP-[%]sialic to precipitate protein and sucrose. After the addition of 1 fig of 
acid (154-351 &i/,4M) was purchased from Amersham GM1 ganglioside (Supelco, PA, USA) the extracts were dried 
(England) and CMP-sialic acid was purchased from New down to 25 ~1 and spotted on 3 MM Whatman paper for ascen- 
England Nuclear (Boston, MA, USA). ding chromatography in 1% Na’ borate, pH 9.1, for 90 min. 
2.2. Methods 
A Golgi and post-Ciolgi membrane fraction (e 1.16-1.18) 
from SW1 116 has been characterized by techniques reported 
141. 
2.2.1. Standard assay for radioactive IV’-NeuNAcLcOse&er 
70 pg of Naf taurocholate was dissolved with 5 tg LcOssCer 
in CHCls/CHsOH, 2: 1, in a conical assay tube. Other com- 
ponents of the incubation were (final concentrations): 
cacodylate (0.15 M), sucrose (0.3 M), M&h (1 mM), CDP- 
choline (0.5 mM), MnClz (1 mM), CMP-[14C]sialic (1OOcM) 
and 6-10 gg membrane protein, all in a total volume of 50 ~1, 
pH 6.3. Incorporation of radioactivity into mono- 
sialoganglioside was linear up to 4 h. 
After the chromatogram was completely dried, the origins 
were excised and extracted again with CHC13/CHsOH/HzO, 
60:35:8, v/v, 3 times each, 2 ml. These extracts were applied 
to DEAE-Sepharose (acetate) columns (1 x 0.5 cm) which were 
eluted subsequently with 3 ml, CHCI~/CH~OH/HZO, 60: 35 : 8 
and 7 ml of 0.03 M NHtOAc- in methanol. The methanol 
fraction was dried down and counted in 0.5 ml methanol and 
10 ml Insta-gel (Packard) against minus glycolipid controls in a 
LKB Beta-Rack programmed counter. 
2.2.3. Neuraminidase specificity assays 
2.2.2. Analysis of the radioactive enzymatic products 
Incubations were terminated by the addition of 0.5 ml of 
Each incubation contained about 500 dpm of i4C-labelled en- 
zymatic product, 7.5 fig taurodeoxycholate, 250 &l en- 
doglycoceramidase in a total volume of 20~1 buffered with 
0.05 M Na+ acetate (pH 5.5), incubated at 37°C for 90 min. 
2O/rg of IV3-NeuNAcLcOse4 (Biocarb, Lund, Sweden) were 
then added and 50 pg of viral sialidase or 10 #U V. cholerae in 
5 /tl of 0.05 M acetate, and the incubating continued for up to 
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Fig. 1. Incorporation of 14C from CMP-[i4C]sialic into monosialoganglioside fractions as a function of glycolipid acceptor 
concentration. (O---O) Galactose oxidase treated LcOsQCer [4]. 
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1 h. Control incubations contained IIIb-NeuNAcLcOw or 
IV6-NeuNAcnLcOsQ (Biocarb). The products were anabsed by 
HPTLC on Merck nanoplaque Si 60 plates in the system 
butanol/AcOH/HrO, 2: 1: 1, v/v and by resorcinol spray for 
oligosaccharide standards and fluorography for the radioactive 
products [6]. 
3. RESULTS AND DISCUSSION 
Of the 4 ‘core’ structures tested, LcOse,&er, 
nLcOse&er, GgOseKer and GbOse&er, intact 
LcOse&er was the best acceptor of sialic acid from 
CMP-[14C]sialic in the presence of SW1116 post- 
Golgi membrane fractions (fig.1). Galactose ox- 
idase pretreatment of the LcOse4Cer [4] destroyed 
most of the acceptor capacity of the glycolipid 
(fig. 1). 
The enzymatic activities responsible for the 
sialylation of other acceptors may be due to the 
presence of other transferases in these membrane 
fractions, or to the presence of an a2-3 
transferase which does not have an absolute 
specificity for the sugar sequence between the ter- 
minal non-reducing galactosyl moieties and the 
ceramide. Sialylation of GgOsedCer to form 
IV3-NeuNAcGgOse4Cer has been recently reported 
171. 
Previous work with a sialyl transferase which 
synthesizes IV3-NeuNAcnLcOse4 in submaxillary 
gland and PC9 lung carcinoma cells appears to in- 
dicate specificity for the nLcOse4 (type 2) sequence 
[8,9] and does not sialylate LcOse4. 
Further purification and characterization of 
sialyl transferases from colorectal carcinoma cells 
are in progress to resolve this issue. 
The migration of the monosialoganglioside 
radioactive product on HPTLC plates in the 
system CHCl3/CH3OH/2.5 M NH3 is shown in 
fig.2. The major product comigrates with authen- 
tic IV3-NeuNAcLcOse.&er just ahead of 
113-NeuNAcGgOse4Cer and not with IV6-Neu- 
NAcnLcOse&er (fig.2). 
Further evidence for the structure of the major 
radioactive enzymatic product was obtained using 
an assay coupling endoglycoceramidase (EGCE) 
[lo] and sialidases from Influenza and K cholerae 
[ 111. EGCE will not release sugars from glycopro- 
teins. We observed about a 60% release of the 
oligosaccharide. Subsequent viral and bacterial 
sialidase activity released up to 90% of the sialosyl 
moiety under conditions which left over 81% of 
Fig.2. Migration of authentic monosialoganglioside on HPTLC 
in relation to the “C-labelled enzymatic product of LcOse&er 
sialylation, in the solvent system CHCls/CHrOH/2.5 M NHs, 
60:40:9. Lanes: 1, IV’-NeuNAcLcOse&er; 2, IV6- 
NeuNAcnLcOse&er; 3, 113-NeuNAcGgOsqCer; A, densito- 
meter tracing of a fluorogram of the t4C-labelled enzymatic 
product after chromatography. 
the IV6-NeuNAcnLcOse4 and 1116-NeuNAcLcOse4 
pentaoses intact. 
To our knowledge this is the first demonstration 
of the @2- 3 sialylation of the terminal galactosyl 
moiety of lactotetraosylceramide of documented 
purity and structure [12]. Our results should be 
useful for determination of this enzymatic activity 
in tissues where monosialogangliosides of the 
lacto-series are either exiguous or cryptic. One 
reason why there is some inconsistency in the 
evidence for the notion of ‘tumor associated’ 
glycolipid antigens is that some of them are the 
limiting substrates for further glycosylation and 
hence do not accumulate sufficiently for detection 
by Mab. The appropriate transferases may, 
nonetheless, be detectable in vitro. 
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5.3. Migration of authentic pentaoses and N-acetylneuraminic acid (NANA) in relation to the 14C-labelled enzymatic product tr 
th endoglycoceramidase (EGCE) and sialidases. Lanes: 1, authentic NANA; 2-7, influenza viral sialidase (10 and 30 min) incub 
th authentic IV’-NeuNAcLcOse4 (2 and 5), 1116-NeuNAcLcOse4 (3 and 6), IV6-NeuNAcnLcOse4 (4 and 7); 11-13 show results 
cholerue incubation for 30 min with IV3-NeuNAcLcOse4 (1 l), 1116-NeuNAcLcOse4 (12), IV6-NeuNAcnLcOse4 (13); 8, 14C-lat 
zymatic product treated with EGCE and viral sialidase, 10 min; 9, 14C-labelled product treated with EGCE and V. cholerue siali 
30 min; 10, 14C-labelled product treated with EGCE only; 14, authentic pentaose treated with buffer only. 
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